Amit K. Tiwari, Ph.D., DABT
Professor, College of Pharmacy and Pharmaceutical Sciences
Professor, College of Medicine and Life Sciences
Director of International Engagement
Department of Pharmacology and Experimental Therapeutics
Frederic and Mary Wolfe Center 282F
Phone: 419.383.1913
Email: amit.tiwari@utoledo.edu
Area of Research
The Tiwari Cancer & Systems Therapeutics Laboratory (CAST Lab) integrates pharmacology and chemical biology tools to 1) ascertain how cancer cells become resistant to anticancer drugs that are mechanistically and structurally distinct, i.e., the development of multidrug resistance (MDR) and 2) develop therapeutic approaches to overcome MDR.
Educational Background
| Postdoctoral Associate | Mount Sinai School of Medicine, NY, 2013 |
| Ph.D. in Pharmaceutical Sciences and Pharmacology | St. John's University, NY, 2011 |
| M.S. in Pharmaceutical Sciences and Pharmacology | St. John's University, NY, 2008 |
| B.S. in Pharmacy | RamEesh Institute, U.P.T.U. University, 2005 |
Scope of Practice
Dr. Tiwari directs the Cancer and Systems Therapeutics (CAST) program at the University of Toledo and holds a joint position in the College of Pharmacy & Pharmaceutical Sciences and College of Medicine & Life Sciences. CAST team is involved in a) developing effective, safe, and targeted anticancer molecules against multidrug-resistant cancers; b) designing, synthesizing and characterizing non-conventional forms of cell death inducers i.e. modulators of necroptosis, methuosis, and autophagy. CAST is also engaged in innovative drug delivery systems, natural products drug discovery, and chemical toxicity. CASTers are particularly interested in the identification of novel targets (single and multi-targets), synthesis and optimization of lead compounds, PK (ADME), PD (i.e. efficacy, model/assay developments, and mechanistic studies), drug-drug/herbal interactions, drug resistance, advanced toxicology assessments, and IP protection and commercialization.
Awards, Honors and Grants
Active Research Grants
- National Cancer Institute, NIH
- National Science Foundation Major Research Instrumentation Grant
- Department of Defense, Breast Cancer Breakthrough Level II Award
- Susan G. Komen Career Catalyst Research Award
- Indo-US STEM Outreach SURF Program
- Ohio Department of Higher Education
- Scleroderma Foundation
Other Recent Awards/Honors
- President's Award for Excellence in Creative and Scholarly Activity, University of Toledo, OH, 2022
- Outstanding Research and Scholarship Award, University of Toledo, OH, 2022
- Distinguished Young Alumni Award, St. Johns University, NY, 2022
- Outstanding Advisor Award, University of Toledo, OH, 2021
- Distinguished Scientist Award, International Association of Pharmacy Professionals, 2021
- Distinguished Speaker Award, AAPS AU Chapter, Auburn University, AL, 2020
- Editorial Travel Award, MDPI Press GICBC Conference, London, UK, 2019
- Distinguished Researcher Award, RIPER, India, 2017
- UT-Scholars Institute Program (SIP) program Fellow, University of Toledo, OH, 2017
- Invited Judge with Travel Award, ABRCMS conference, 2014, 2015, 2017, 2018
- Global Research Engagement Award, JNTUA/RIPER/Govt. of Andhra P, India, 2017
- Young Investigator Award, Synergy Cancer Pharmacology Conference, NY, 2017
- ‘Chandrabose et al. 2017’ appeared on the cover of ‘Bioorg Med Chem Lett’, 2017
Editor/Associate Editor
- Editor in Chief: Cancer Reports, Wiley Press
- Associate Editor: Frontiers in Pharmacology; Frontiers in Oncology; Frontiers in Toxicology
- Special Issue Editor: Cancers, Frontiers in Oncology
- Section Editor – Current Pharmaceutical Design
- Editorial Board - Over 15 journals including Drug Resistance Updates
Grant Reviewer
- Geneva UHFMR Foundation Grants, Switzerland
- University of Sharjah, UAE, Competitive Res Grant
- International Union for Cancer Control (UICC)
- Department of Defense, BCRP Section
- Graduate Women in Science (GWIS)
- National Science Center, Poland
- INBRE-DRPP, Nebraska
- Jack Brockhoff Foundation, Australia
- NABP AACP District IV grant proposals
- Environmental Protection Agency (EPA), Chemical Safety
- National Institute of Health, XNDA study section
- Environmental Protection Agency (EPA), Chemical Safety
- National Science Foundation-GRFP
- Medical Research Council, UK-ASM Newton Fund
- Macquarie University Research Fellowships, Australia
Publications
Patent Applications
- Raman D, Howard C, Nemunitis J, Brunicardi FC, Liu SH, and Tiwari AK. Targeting LASP1, elF4A1, e1F4B and CXCR4 with modulators And Combinations Thereof for Cancer Therapy (provisional D-2019-32, Ser. No. 62/807,075.) 2019
- Tiwari AK, Hussein N, Ashby CR. Cariprazine and its analogues use in cancer therapy. (Application 60893-US-PSP/D2019-33, No. 62/934,638) 2019
- Tiwari AK, Karthikeyan C, Nyinawabera, A. Necroptosis inducers and autophagy inhibitors in cancer therapy. (US patent application 2018, 60088-US-PSP/D2018-45).
- Tiwari AK, Karthikeyan C, Amawi H, Erhardt P and Trivedi P. Materials and Methods Useful to Induce Cancer Cell Death Via Methuosis Or Autophagy Or A Combination Thereof. (US patent application 2017, 59593-US-PSP/D2018-15). Published 08-09-2022 - US11406626B2